Anatara Lifesciences Ltd
ANR
Company Profile
Business description
Anatara Lifesciences Ltd develops and commercializes evidence-based products addressing unmet needs in gastrointestinal health. The company focuses on building a pipeline of human health products, particularly targeting complex gastrointestinal conditions. It operates through a single reportable segment encompassing the research and development of oral solutions for gastrointestinal diseases and the commercialization of Detach, a diarrhea treatment for piglets.
Contact
c/- Perks, 81 Flinders Street
Level 8
AdelaideSA5000
AUST: +61 438027172
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
Employees
Stocks News & Analysis
stocks
Anthropic’s leaked financials reflect fast growth, but not a $2 trillion valuation
Draft IPO filing shows a company growing faster than its annual results can capture.
stocks
The 10 best US companies to invest in now
The stocks of these high-quality companies look cheap today.
stocks
Surge in combat drones drives upgrade for ASX share
Drone demand powers growth but investor optimism is overdone.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,859.20 | 4.50 | 0.05% |
| CAC 40 | 7,834.10 | 63.09 | -0.80% |
| DAX 40 | 25,254.21 | 23.01 | 0.09% |
| Dow JONES (US) | 51,267.90 | 90.94 | 0.18% |
| FTSE 100 | 10,497.94 | 35.99 | 0.34% |
| HKSE | 24,040.34 | 68.05 | 0.28% |
| NASDAQ | 27,477.31 | 286.45 | 1.05% |
| Nikkei 225 | 69,946.86 | 1,637.40 | 2.40% |
| NZX 50 Index | 13,701.63 | 2.61 | 0.02% |
| S&P 500 | 7,773.95 | 51.23 | 0.66% |
| S&P/ASX 200 | 8,686.40 | 4.30 | 0.05% |
| SSE Composite Index | 3,842.19 | 11.74 | 0.31% |